A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic …
M Silva, J Poo, F Wagner, M Jackson, D Cutler… - Journal of …, 2006 - Elsevier
BACKGROUND/AIMS: To compare the pharmacokinetics, pharmacodynamics, and antiviral
activity of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C
virus genotype 1. METHODS: Thirty-six patients were randomised to peginterferon alfa-2b
(1.5 μg/kg/week) or peginterferon alfa-2a (180μg/week) for 4 weeks, then in combination
with ribavirin (13mg/kg/day) for a further 4 weeks. The pharmacokinetic profile of both
peginterferons, mRNA expression of a selected group of interferon-induced gene transcripts …
activity of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C
virus genotype 1. METHODS: Thirty-six patients were randomised to peginterferon alfa-2b
(1.5 μg/kg/week) or peginterferon alfa-2a (180μg/week) for 4 weeks, then in combination
with ribavirin (13mg/kg/day) for a further 4 weeks. The pharmacokinetic profile of both
peginterferons, mRNA expression of a selected group of interferon-induced gene transcripts …